Journal
CELL DEATH & DISEASE
Volume 11, Issue 1, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-020-2241-6
Keywords
-
Categories
Funding
- UK Medical Research Council (MRC)
- UK MRC
- U.K. MRC [MC_UU_12016/3]
- Boehringer-Ingelheim
- GlaxoSmithKline
- Merck-Serono
- MRC [MC_UU_00018/6, MC_UU_12016/3, MR/R021406/1] Funding Source: UKRI
Ask authors/readers for more resources
The signalling pathways initiated by members of the transforming growth factor-beta (TGF beta) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGF beta signalling is therefore strictly regulated to ensure appropriate context-dependent physiological responses. In an attempt to identify novel regulatory components of the TGF beta signalling pathway, we performed a pharmacological screen by using a cell line engineered to report the endogenous transcription of the TGF beta-responsive target gene PAI-1. The screen revealed that small molecule inhibitors of salt-inducible kinases (SIKs) attenuate TGF beta-mediated transcription of PAI-1 without affecting receptor-mediated SMAD phosphorylation, SMAD complex formation or nuclear translocation. We provide evidence that genetic inactivation of SIK isoforms also attenuates TGF beta-dependent transcriptional responses. Pharmacological inhibition of SIKs by using multiple small-molecule inhibitors potentiated apoptotic cell death induced by TGF beta stimulation. Our data therefore provide evidence for a novel function of SIKs in modulating TGF beta-mediated transcriptional and cellular responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available